Related Experiment Video
Updated: Sep 29, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Systemic Metabolic and Inflammatory Changes Associated with Helicobacter Pylori Eradication: A Controlled
Ali Zeynettin1, Selin Ozdemir2, Sibel Bilgili3
1Department of Internal Medicine, İzmir City Hospital, İzmir, Türkiye. alizeynettin@gmail.com.
Background And Aims:
Helicobacter pylori (H. pylori) infection has been linked to systemic metabolic and inflammatory disturbances beyond the gastric mucosa, yet evidence regarding biomarker changes after eradication remains heterogeneous. This study evaluated systemic metabolic and inflammatory changes associated with eradication success versus persistent infection, using H. pylori-negative controls within a controlled before-after cohort framework.
Methods:
Adults undergoing stool H. pylori antigen testing at a tertiary referral center in Türkiye (2020-2025) with paired baseline (pre) and follow-up (post) laboratory measurements were included. Participants were classified as H. pylori-negative controls, eradication success (baseline positive, follow-up negative), or eradication failure (baseline and follow-up positive). Co-primary endpoints were follow-up HOMA-IR and hsCRP (log-transformed), compared between groups using ANCOVA adjusted for baseline values and prespecified covariates. Prespecified supportive analyses used a difference-in-differences framework. Secondary outcomes included glycemic measures, lipid profile, hematological inflammation indices, and liver-related biomarkers; TyG index and FIB-4 were assessed exploratorily.
Results:
A total of 3,756 individuals were included (1,321 controls; 1,847 eradication success; 588 eradication failure). In adjusted analyses, eradication success showed a more favorable follow-up profile with lower insulin resistance and systemic inflammation compared with controls, whereas eradication failure showed an opposing pattern. Directionally consistent differences were also observed across secondary metabolic, inflammatory, and hepatic biomarkers and were supported by difference-in-differences analyses.
Conclusions:
Compared with H. pylori-negative controls, eradication success was associated with a more favorable systemic short-term metabolic-inflammatory profile, whereas persistent infection tended to show the opposite pattern. Prospective studies with longer follow-up are needed to determine durability and clinical relevance.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Gastritis II: Pathophysiology
01:24Peptic Ulcer Disease II: Pathophysiology
01:27Peptic Ulcer
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...